Safety of high-dose naltrexone treatment: Hepatic transaminase profiles among outpatients

Suck W Kim, Jon E. Grant, Gihyun Yoon, Kyle A. Williams, Rory P Remmel

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

OBJECTIVES: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. METHODS: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. RESULTS: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). CONCLUSIONS: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.

Original languageEnglish (US)
Pages (from-to)77-79
Number of pages3
JournalClinical Neuropharmacology
Volume29
Issue number2
DOIs
StatePublished - Mar 1 2006

Fingerprint

Naltrexone
Transaminases
Outpatients
Safety
Disruptive, Impulse Control, and Conduct Disorders
Liver
Therapeutics
Acetaminophen
Aspartate Aminotransferases
Alanine Transaminase
Aspirin
Analgesics
Reference Values
Anti-Inflammatory Agents
Pharmaceutical Preparations

Keywords

  • Alanine transaminase
  • Aspartate transaminase
  • Hepatotoxicity
  • Impulse-control disorders
  • NSAID
  • Naltrexone
  • Nonsteroidal anti-inflammatory drugs
  • Pathologic gambling disorder

Cite this

Safety of high-dose naltrexone treatment : Hepatic transaminase profiles among outpatients. / Kim, Suck W; Grant, Jon E.; Yoon, Gihyun; Williams, Kyle A.; Remmel, Rory P.

In: Clinical Neuropharmacology, Vol. 29, No. 2, 01.03.2006, p. 77-79.

Research output: Contribution to journalArticle

Kim, Suck W ; Grant, Jon E. ; Yoon, Gihyun ; Williams, Kyle A. ; Remmel, Rory P. / Safety of high-dose naltrexone treatment : Hepatic transaminase profiles among outpatients. In: Clinical Neuropharmacology. 2006 ; Vol. 29, No. 2. pp. 77-79.
@article{1ef60dc7947d4193b6f858245dbef470,
title = "Safety of high-dose naltrexone treatment: Hepatic transaminase profiles among outpatients",
abstract = "OBJECTIVES: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. METHODS: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. RESULTS: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). CONCLUSIONS: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.",
keywords = "Alanine transaminase, Aspartate transaminase, Hepatotoxicity, Impulse-control disorders, NSAID, Naltrexone, Nonsteroidal anti-inflammatory drugs, Pathologic gambling disorder",
author = "Kim, {Suck W} and Grant, {Jon E.} and Gihyun Yoon and Williams, {Kyle A.} and Remmel, {Rory P}",
year = "2006",
month = "3",
day = "1",
doi = "10.1097/00002826-200603000-00004",
language = "English (US)",
volume = "29",
pages = "77--79",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Safety of high-dose naltrexone treatment

T2 - Hepatic transaminase profiles among outpatients

AU - Kim, Suck W

AU - Grant, Jon E.

AU - Yoon, Gihyun

AU - Williams, Kyle A.

AU - Remmel, Rory P

PY - 2006/3/1

Y1 - 2006/3/1

N2 - OBJECTIVES: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. METHODS: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. RESULTS: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). CONCLUSIONS: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.

AB - OBJECTIVES: This study was carried out to test the hypothesis that the hepatic safety profile of prolonged high-dose oral naltrexone (150 mg/d) is acceptable if over-the-counter analgesic use is restricted. METHODS: Data from 41 consecutive outpatients with impulse-control disorder receiving naltrexone therapy were analyzed. RESULTS: The mean treatment duration was 328 days and the mean naltrexone dose was 142 mg/d. Pretherapy/posttherapy mean aspartate transaminase and alanine transaminase levels in the naltrexone-alone group were 21.79/22.54 and 21.74/21.49 U, respectively (all within reference range). CONCLUSIONS: Although limited in scope, these findings support the hypothesis that long-term use of high-dose oral naltrexone is safe in otherwise healthy patients with impulse-control disorders who restrict their intake of acetaminophen, aspirin, or nonaspirin nonsteroidal anti-inflammatory drugs (NSAID). However, confirming studies are needed.

KW - Alanine transaminase

KW - Aspartate transaminase

KW - Hepatotoxicity

KW - Impulse-control disorders

KW - NSAID

KW - Naltrexone

KW - Nonsteroidal anti-inflammatory drugs

KW - Pathologic gambling disorder

UR - http://www.scopus.com/inward/record.url?scp=33646934982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646934982&partnerID=8YFLogxK

U2 - 10.1097/00002826-200603000-00004

DO - 10.1097/00002826-200603000-00004

M3 - Article

C2 - 16614539

AN - SCOPUS:33646934982

VL - 29

SP - 77

EP - 79

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 2

ER -